3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Not yet recruiting
3
Active not recruiting
2
Terminated
1
Recruiting
1
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Urinary Bladder Neoplasms
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Interventions
pembrolizumab
68
Cyclophosphamide
46
Cisplatin
43
Nivolumab
36
Paclitaxel
33
Carboplatin
31
Radiotherapy
29
Gemcitabine
28
Docetaxel
25
Dexamethasone
22
atezolizumab
21
Bevacizumab
20
Doxorubicin
19
Magnetic Resonance Spectroscopy
18
Blood Specimen Collection
18
Radiosurgery
17
fludarabine
16
Vincristine
16
Lenalidomide
16
Etoposide
16
Letrozole
15
Ipilimumab
15
Fluorouracil
15
palbociclib
14
Surveys and Questionnaires
14
Rituximab
14
Radiation
14
Leucovorin
14
Cytarabine
14
durvalumab
13
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Cystectomy
×
90 days
×
Clear all
NCT03924856
2026-05-28
KEYNOTE-866
Merck Sharp & Dohme LLC
Phase 3
Completed
907 enrolled